It is the cache of ${baseHref}. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Pegylated liposomal doxorubicin: appraisal of its current role in the
skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

14789

Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer



Review

(4563) Total Article Views


Authors: Markman M

Published Date June 2011 Volume 2011:3 Pages 219 - 225
DOI: http://dx.doi.org/10.2147/CMAR.S15558

Maurie Markman
Cancer Treatment Centers of America, Eastern Regional Medical Center, Philadelphia, PA, USA

Abstract: Pegylated liposomal doxorubicin (PLD) has become a major component in the routine management of epithelial ovarian cancer. The drug is frequently employed as a single agent in the platinum-resistant setting, and recently reported data reveal the superiority of the combination of PLD plus carboplatin, compared with the platinum drug plus paclitaxel, in delaying the time to disease progression in women with recurrent (potentially platinum-sensitive) disease. Current research efforts involving PLD in ovarian cancer are focusing on adding novel targeted drugs to this cytotoxic agent. The utility of such approaches in the platinum-resistant population, compared with the sequential administration of single agents active in this setting, remains to be determined.

Keywords: PLD, carboplatin, paclitaxel, platinum-sensitive, platinum-resistant


Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

 

Other articles by Dr Maurie Markman


Readers of this article also read: